News

NuVision® are delighted to announce that they have signed a distribution agreement with Doctrinemed, a Turkish pharmaceutical and medical device company with a focus on ophthalmology. Doctrinemed will be working closely with NuVision in order to distribute our sight saving regenerative therapy, Omnigen® as well as...

3 August 2018 - Sygnature Discovery, a leading independent provider of integrated drug discovery and pre-clinical services and expertise, has proven its commitment to cyber security and the protection of its clients’ data by obtaining Cyber Essentials Plus certification. Launched by the UK Government in 2014,...

Sygnature Discovery has appointed Dr Andy Black as non-executive Chairman. Andy will work closely with the Board and senior team to further develop the future growth strategy of the organisation. In October 2017, Phoenix Equity Partners, a leading private equity investor in medium-sized, UK-based companies, invested...